CA3175526A1 - Pirfenidone for coronavirus treatment - Google Patents

Pirfenidone for coronavirus treatment

Info

Publication number
CA3175526A1
CA3175526A1 CA3175526A CA3175526A CA3175526A1 CA 3175526 A1 CA3175526 A1 CA 3175526A1 CA 3175526 A CA3175526 A CA 3175526A CA 3175526 A CA3175526 A CA 3175526A CA 3175526 A1 CA3175526 A1 CA 3175526A1
Authority
CA
Canada
Prior art keywords
approximately
pirfenidone
release
subject
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175526A
Other languages
English (en)
French (fr)
Inventor
Estuardo Aguilar-Cordova
Laura AGUILAR
Jose Agustin Rogelio Magana Castro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excalibur Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3175526A1 publication Critical patent/CA3175526A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
CA3175526A 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment Pending CA3175526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
US63/010,009 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (1)

Publication Number Publication Date
CA3175526A1 true CA3175526A1 (en) 2021-10-21

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175526A Pending CA3175526A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Country Status (14)

Country Link
US (1) US20230117397A1 (enExample)
EP (1) EP4135671A4 (enExample)
JP (1) JP2023521887A (enExample)
KR (1) KR20230038644A (enExample)
CN (1) CN115916162A (enExample)
AU (1) AU2021254765A1 (enExample)
BR (1) BR112022020821A2 (enExample)
CA (1) CA3175526A1 (enExample)
CL (1) CL2022002843A1 (enExample)
CO (1) CO2022016155A2 (enExample)
EC (1) ECSP22087664A (enExample)
IL (1) IL297296A (enExample)
MX (1) MX2022012986A (enExample)
WO (1) WO2021211745A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
WO2003030720A2 (en) * 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
US20070072181A1 (en) * 2003-02-28 2007-03-29 Blatt Lawrence M Combination therapy for treating alphavirus infection and liver fibrosis
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
MX2007014114A (es) * 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
SG176053A1 (en) * 2009-05-15 2011-12-29 Intermune Inc Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
EP4491180A1 (en) * 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof

Also Published As

Publication number Publication date
US20230117397A1 (en) 2023-04-20
EP4135671A1 (en) 2023-02-22
IL297296A (en) 2022-12-01
EP4135671A4 (en) 2024-08-14
WO2021211745A1 (en) 2021-10-21
BR112022020821A2 (pt) 2022-12-20
CL2022002843A1 (es) 2023-09-01
MX2022012986A (es) 2023-03-21
ECSP22087664A (es) 2022-12-30
AU2021254765A1 (en) 2022-12-08
KR20230038644A (ko) 2023-03-21
JP2023521887A (ja) 2023-05-25
CO2022016155A2 (es) 2022-12-20
CN115916162A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
US20230117397A1 (en) Pirfenidone for coronavirus treatment
CN114786659B (zh) 用于治疗汉坦病毒感染的mek抑制剂
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
JP2007291067A (ja) 医薬組成物
JP7701757B2 (ja) タウロデオキシコール酸またはその薬学的に許容される塩を有効成分として含む新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療用組成物
JP2023521887A5 (enExample)
US12064509B2 (en) Enema for rectal application
CA3190278A1 (en) Antiviral use of liraglutide and gefitinib
JP2010083871A (ja) 抗アデノウイルス剤を含有する医薬組成物
JP5134802B2 (ja) 塩酸ブロムヘキシン含有量低下の防止方法
CN101966190A (zh) 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
JP2023523410A (ja) 上気道感染症を治療するための組成物および方法
JP2004331660A (ja) 医薬組成物
ZA200500064B (en) Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
CN119139378A (zh) 神香草挥发油及包含其的组合物在制备治疗特发性肺纤维化药物中的应用
Habawel et al. Comparative Efficacy of Different Fixed Drug Combinations on Clinical Signs of Respiratory Disease in Starter Pigs.
CN105362226A (zh) 氨溴索沙丁胺醇气雾剂的制备方法
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
KR20230098780A (ko) 코로나바이러스에 대한 티아졸리드의 용도
CN105456240A (zh) 氨溴索沙丁胺醇气雾剂
KR20150063040A (ko) 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제
CN102552257A (zh) 一种含有盐酸雷尼替丁和曲昔派特的复方制剂及其用途
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
CN105434412A (zh) 氨溴索沙丁胺醇控释胶囊

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250929

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203